SODIUM POLYPHOSPHATE-TIN KIT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Polyphosphate-Tin Kit is an injectable diagnostic agent approved in 1976 for radiopharmaceutical imaging. The product's mechanism of action and specific therapeutic indications are not publicly detailed in available records. It is administered via injection and represents a legacy diagnostic modality from the nuclear medicine era.
LOE Approaching
This legacy diagnostic product faces imminent loss of exclusivity with minimal current commercial activity and declining relevance in modern imaging protocols.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product generates zero linked job opportunities, indicating minimal or no active hiring or career momentum. Working on a legacy diagnostic product approaching LOE offers limited advancement potential and primarily involves portfolio maintenance and compliance work.
Diagnostic Product ManagerField Sales (Diagnostic)
Worked on SODIUM POLYPHOSPHATE-TIN KIT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.